Results 11 to 20 of about 118,941 (325)

Sodium-glucose co-transporter-2 inhibitors: A cardiovascular outcome trial analysis

Perspectives in Clinical Research, 2021
Cardiovascular outcome trials (CVOTs) have to be done by sponsors who wish to launch new antidiabetic drugs in the US, since the December 2008 US Food and Drug Administration ruling, which was subsequently accepted by the European Medicines (Evaluation ...
Viraj Ramesh Suvarna
doaj   +4 more sources

Safety of Sodium-Glucose Co-Transporter 2 Inhibitors. [PDF]

The American Journal of Cardiology, 2019
Sodium-glucose co-transporter 2 (SGLT2) inhibitors have a well-defined safety profile based on data obtained from numerous clinical trials, including cardiovascular outcomes trials (CVOTs) and postmarketing pharmacovigilance reporting.
J. McGill, S. Subramanian
semanticscholar   +4 more sources

Sodium glucose co-transporter 2 inhibitors in heart failure therapy

Türk Kardiyoloji Derneği Arşivi, 2020
Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) are a new class of drugs for patients with type 2 diabetes (T2DM) which inhibit urinary glucose reabsorption in the proximal tubule of the nephron and result in glucosuria, natriuresis and diuresis.
Yüksel Çavuşoğlu, Hakan Altay, Avivit Cahn, Ahmet Celik, Serafettin Demir, Barış Kılıçaslan, Sanem Nalbantgil, Itamar Raz, Ahmet Temizhan, Özlem Yıldırımtürk, Mehmet Birhan Yılmaz   +10 more
doaj   +5 more sources

Editorial: Sodium Glucose Co-Transporter 2 Inhibitors and Kidney Function

Frontiers in Pharmacology, 2022
Daniel H. Van Raalte, Hiddo Lambers Heerspink   +1 more
doaj   +4 more sources

Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors

Cardio-Oncology
Background Immune checkpoint inhibitors (ICIs) have revolutionized the prognosis of cancer. Diabetes mellitus (DM) has been shown to have a negative effect on patients treated with ICIs.
Moran Gvili Perelman, Rafael Y. Brzezinski, Barliz Waissengrin, Yasmin Leshem, Or Bainhoren, Tammi Arbel Rubinstein, Maxim Perelman, Zach Rozenbaum, Ofer Havakuk, Yan Topilsky, Shmuel Banai, Ido Wolf, Michal Laufer-Perl   +12 more
doaj   +3 more sources

Sodium-glucose co-transporter 2 inhibitors beyond diabetes

Australian Prescriber, 2022
Sodium-glucose co-transporter 2 (SGLT2) inhibitors lower blood glucose by reducing the reabsorption of glucose in the kidney. They are a second-line therapy for type 2 diabetes. During clinical trials it was noticed that SGLT2 inhibitors had favourable effects on cardiovascular and renal disease.
Williams, Dimity L., Rofail, Serena, Atherton, John J.   +2 more
openaire   +3 more sources

Sodium-glucose co-transporter-2 inhibitors and epicardial adiposity

European Journal of Pharmaceutical Sciences, 2023
Epicardial adipose tissue is a layer of adipocytes that physiologically surround the myocardium and play some physiologic roles in normal heart function. However, in pathologic conditions, the epicardial adipose tissue can present a potent cardiac risk factor that is capable of impairing heart function through several pathways, increasing the risk of ...
Habib Yaribeygi, Mina Maleki, Alexandra E. Butler, Tannaz Jamialahmadi, Amirhossein Sahebkar   +4 more
openaire   +2 more sources

Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor [PDF]

Korean Journal of Medicine, 2014
Correspondence to Jeong Hyun Park, M.D., Ph.D. Paik Institute for Clinical Research, Department of Internal Medicine, Pusan Paik Hospital, Inje University College of Medicine, 75 Bokji-ro, Busanjin-gu, Busan 614-735, Korea Tel: +82-51-890-6074, Fax: +82-51-892-0273, E-mail: pjhdoc@chol.com Copyrightc 2014 The Korean Association of Internal Medicine ...
Mi-kyung Kim, Jeong Hyun Park
openaire   +1 more source

Sodium glucose co-transport 2 inhibitors for gout treatment

Discoveries, 2022
Hyperuricemia remains the most prevalent cause of gout. Gout patients present with joint inflammation and uric acid crystals deposition manifesting as tophi. The association of gout with increased risk of insulin resistance, diabetes, metabolic disorders, increased cardiometabolic risk, and kidney disease is well established.
Somagutta, Manoj Kumar Reddy, Luvsannyam, Enkhmaa, Jain, Molly, Cuddapah, Gaurav Venkat, Pelluru, Sandeep, Mustafa, Nafisa, Nasereldin, Duaa S., Pendyala, Siva K., Jarapala, Nagendrababu, Padamati, Bhavani   +9 more
openaire   +2 more sources

Harms and benefits fo sodium-glucose co-transporter 2 inhibitors [PDF]

Australian Prescriber, 2020
Sodium-glucose co-transporter 2 inhibitors are oral glucose-lowering drugs that increase the urinary excretion of glucose. In patients with type 2 diabetes and cardiovascular disease they reduce all-cause mortality, cardiac mortality, rates of hospitalisation for heart failure and the progression of renal disease There are adverse effects related to ...
Chesterman, Thomas, Thynne, Tilenka RJ
openaire   +2 more sources